IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS Conference Paper uri icon

published proceedings

  • VALUE IN HEALTH

author list (cited authors)

  • Berrios, K., Burum, A., Jeong, E., & Zhong, L.

complete list of authors

  • Berrios, K||Burum, A||Jeong, E||Zhong, L

publication date

  • January 2022